A Phase I Study of EC90 [keyhole limpet haemocyanin fluorescein isothiocyanate conjugate] with GPI-0100 adjuvant followed by EC17 [folate fluorescein isothiocyanate conjugate] with cytokines (interleukin-2 [IL-2] and interferon-alpha [IFN-alpha]) in patients with refractory or metastatic cancer.

Trial Profile

A Phase I Study of EC90 [keyhole limpet haemocyanin fluorescein isothiocyanate conjugate] with GPI-0100 adjuvant followed by EC17 [folate fluorescein isothiocyanate conjugate] with cytokines (interleukin-2 [IL-2] and interferon-alpha [IFN-alpha]) in patients with refractory or metastatic cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2012

At a glance

  • Drugs Folate-fluorescein isothiocyanate conjugate; GPI 0100; Interferon alpha; Interleukin-2; Keyhole limpet haemocyanin-fluorescein isothiocyanate conjugate
  • Indications Cancer; Renal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Mar 2012 Last checked against ClinicalTrials.gov record.
    • 16 Jun 2008 Actual end date changed from Dec 2007 to Jun 2008 as reported by ClinicalTrials.gov.
    • 07 Feb 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top